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Abstract
Background: Recombinant bone morphogenetic protein two (rhBMP2) has been utilised for a variety of clinical
applications in orthopaedic surgery and dental procedures. Despite its widespread use, concerns have been raised
regarding its short half-life and transient bioactivity in vivo. Recent investigation aimed at developing rhBMP2
synthesized from a shorter polypeptide chain (108 amino acids) has been undertaken.
Methods: The osteopromotive properties of BMP2 were investigated on cell behaviour. Five concentrations of
rhBMP2_108 including 10, 50, 100, 200 and 500 ng/ml were compared to a commercially available rhBMP2 (100 ng/ml).
Each of the working concentrations of rhBMP2_108 were investigated on MC3T3-E1 osteoblasts for their ability to
induce osteoblast recruitment, proliferation and differentiation as assessed by alkaline phosphatase (ALP) staining,
alizarin red staining, and real-time PCR for genes encoding ALP, osteocalcin (OCN), collagen-1 (COL-1) and Runx2.
Results: The results demonstrate that all concentrations of rhBMP2_108 significantly improved cell recruitment and
proliferation of osteoblasts at 5 days post seeding. Furthermore, rhBMP2_108 had the most pronounced effects on
osteoblast differentiation. It was found that rhBMP2_108 had over a four fold significant increase in ALP activity at seven
and 14 days post-seeding and the concentrations ranging from 50 to 200 ng/ml demonstrated the most pronounced
effects. Analysis of real-time PCR for genes encoding ALP, OCN, COL-1 and Runx2 further confirmed dose-dependant
increases at 14 days post-seeding. Furthermore, alizarin red staining demonstrated a concentration dependant increase
in staining at 14 days.
Conclusion: The results from the present study demonstrate that this shorter polypeptide chain of rhBMP2_108 is
equally as bioactive as commercially available rhBMP2 for the recruitment of progenitor cells by facilitating their
differentiation towards the osteoblast lineage. Future in vivo study are necessary to investigate its bioactivity.
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Background
The use of growth factors and biomaterials with bone
inducing properties has played a pivotal role in treat-
ment options for patients suffering from a variety of
bone defects caused by either fracture or disease [1–3].
Osteoporosis, a disease characterized by low mineral
density and subsequent fragility [4] has now reached an
estimated 200 million people worldwide with 80 % being
post-menopausal women [5–7]. The significant increase
in bone metabolic diseases in combination with trau-
matic injuries caused by sports accidents, motor vehicle
accidents and other related fractures necessitates bone
inducing agents capable of speeding up bone regener-
ation often in compromised scenarios such as osteopor-
otic related fractures [8–11].
One growth factor that has been widely used with
FDA approval is that of bone morphogenetic proteins
(BMPs) [12–14]. BMPs were initially extracted from
demineralized bone matrix and it was revealed that these
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low-molecular weight proteins demonstrated the ability to
form ectopic bone in extra-skeletal sites in animals [15, 16].
Since then, BMPs have been capable of regenerating a
multitude of osseous defects and have been shown to im-
prove cell recruitment, proliferation and differentiation of
mesenchymal cells, and speeding up their differentiation
towards bone forming osteoblasts [17]. Despite the clinical
advantages of recombinant proteins, concerns have been
raised regarding their transient bioactivity, protein insta-
bility, fast dissolution rates and short half lives [18]. For
these reasons, the use of rhBMPs are typically administered
in high supra-physiological doses that bear the risk of po-
tential side effects associated with their use [19]. Further-
more, other factors that could lead to a reduced in vivo
bioactivity include the role of antagonists and their specifi-
city for different BMPs (noggin, chordin, dan), the role of
the host organism for expression (E.coli vs. CHO) and the
associated differences in glycosylation patterns that might
lead to differences in bioavailability and stability [20–22].
Recently the development of a novel recombinant pro-
tein fabricated from a shorter polypeptide chain of
BMP2 has been undertaken with the aim of improving
protein stability in vivo. This shorter protein chain is hy-
pothesized to facilitate protein folding, thus potentially
improving the bioactivity of rhBMP2 by increasing the
half-life of the protein [23]. However, prior to animal
testing, a full characterization of this shorter amino acid
sequence was investigated on cell behaviour in vitro.
MC3T3-E1 pre-osteoblasts were investigated for their
response to five different concentrations of rhBMP2_108
including 10, 50, 100, 200 and 500 ng/ml and compared
to control commercially available rhBMP2 at a concen-
tration of 100 ng/ml (R&D systems). rhBMP2_108 was
tested for its ability to induce cell recruitment, cell pro-
liferation, alkaline phosphatase activity, alizarin red
staining as well as mRNA levels for genes encoding alka-
line phosphatase, osteocalcin, collagen one and Runx2 as
assessed by real-time PCR.
Methods
rhBMP2_108 amino acid sequence
rhBMP2_108 was kindly provided by Jiuyuan biotech
company (Hangzhou, China). The shortened amino acid
sequence was fabricated as follows: MKKLKSSCK
RHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPF
PLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAI
SMLYLDENEKVVLKNYQDMVVEGCGCR for a pro-
tein chain of 108 amino acids. The commercially
available BMP2 was purchased from R&D systems
(Minneapolis, USA).
Preparation of BMP2
According to the amino acid sequence, intracellular ex-
pression of rhBMP2_108 in E. coli was constructed for
bulk production of rhBMP2_108 as previously described
[24]. Briefly, the sequence of BMP2 was designed ac-
cording to its amino acid sequence, and then was reverse
transcribed with reverse transcriptase (Gibco BRL, NY,
USA) as previously described [24]. Polymerase chain re-
action (PCR) was used to amplify the cDNA encoding
the shortened amino acid sequence rhBMP2_108 pro-
tein. This rhBMP2_108 cDNA was then subcloned using a
pRSET(A) vector (Invitrogen, UK) to yield the pRSET(A)/
rhBMP2_108 expression vector. Then, pRSET(A)/rhB
MP2_108 was further utilized to transform the E. coli
BL21(DE3) strain. A bioreactor was then utilized to yield
high cell-density cultivation of E. coli. Briefly, transformed
E. coli was cultured in a 5 L fermenter, with 3 L of the de-
fined medium (batch culture; yeast extract 1 g/L, peptone
2 g/L) inoculated with the pre-culture (10 % of the batch
culture volume). The cultivation was performed with stir-
ring at 250 rpm for 48 h at 30 °C, including the addition of
a nutrient medium (glucose 33.3 g/L, peptone 10 g/L, yeast
extract 5 g/L,MgSO41 g/L, FeSO48.0 g/L, CaCl20.048 g/L,
ZnSO40.0176 g/L, CuSO40.008 g/L).
The cultured biomass was then harvested by crushing
twice the cells in a French press and thereafter centrifuged.
The pellet was resuspended at 25 mg wet weight/ml
in a suspension buffer (20 mMTris–HCl [pH 8.5],
0.5 mMEDTA, 2 % [v/v]Triton X-100). The inclusion
bodies (pellets) were resuspended in a solubilization buffer
(6Mguanidine-HCl, 0.1 M Tris–HCl [pH 8.5],0.1 M DTT,
1 mM EDTA) and thereafter incubated with constant stir-
ring at room temperature overnight. Insoluble particles
were then removed from the suspension by centrifugation.
A Heparin Sepharose 6 Fast Flow column was then
used to purify the active rhBMP2_108 (dimer). A con-
tinuous NaCl gradient (0.1–1.5 M) was used to elute the
bound protein. Afterwards, a stepped NaCl gradient
(0.15 M, 0.3 M, and 0.5 M) was used to elute and
separate the active rhBMP2_108 protein. Thereafter
rhBMP2_108 powder was frozen at−20 °C. When used,
0.1 % acetic acid was utilized to dissolve the BMP2
powder. Control rhBMP2 was purchased from R & D
systems (Minneapolis, USA) derived from CHO cells.
Two-dimensional migration assay
MC3T3-E1 pre-osteoblast cell line was used for this study.
No human or animal samples were utilized and thus no
ethical consent was required. The migration assay of cells
was performed with a Transwell chamber using a 24-well
plate and polycarbonate filters (Transwell Costar, Corning,
Acton, MA) with a pore size of 8 μm as previously
described [25]. 104 MC3T3-E1 cells in 50 μl DMEM were
seeded in the upper compartment. rhBMP2_108 at
concentrations of 0, 10, 50, 100, 200 and 500 ng/ml and
control rhBMP2 at 100 ng/ml were seeded into the lower
compartment. The cells were allowed to migrate for 24 h
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at 37 °C in a humidified 5 % CO2 atmosphere. The filter
was then removed, cells were fixed in 4 % formaldehyde
for 20 min and washed in PBS, after washings, filters were
incubated for 15 min at room temperature with Methylro-
sanilnium Chloride Solution (Wuhan Google biotechnol-
ogy limited company G1014), then the filters were washed
with PBS for 10 min. Samples were examined by micros-
copy. Non-migrated cells on the upper side were elimi-
nated by rinsing the filter with cold PBS and scraping with
a rubber wiper. The remaining migrated cells on the lower
side of the filter were counted in nine random fields per
filter (×100 magnification). All samples were performed in
triplicate with 3 independent experiments performed.
Proliferation assay
To investigate the effect of rhBMP2_108 on the prolifera-
tion of MC3T3-E1, CCK-8 assay for each group was per-
formed as previously described [26]. Briefly, cells were
seeded in 96-well plates at a density of 5×103 cells/well. At
time points 1, 3 and 5 days, the CCK-8 assay was per-
formed by adding 10 μL of the CCK-8 solution (Dojindo
Molecular Technologies, Inc. Japan) to each well and in-
cubating for 1.5 h according to manufacturer’s protocol.
The absorbance was measured at λ = 450 nm on a plate
reader. Results were demonstrated as the absorbance of
each experimental well minus the optical density value of
blank wells. All samples were repeated in triplicate with
three independent experiments.
Alkaline phosphatase activity
Alkaline phosphatase activity was analyzed colori-
metrically using alkaline phosphatase assay kit (Nanjing
Jiancheng Bioengineering Insitute) using a starting seed-
ing density of 50’000 cells per 24 well dish as previously
described [27, 28]. At time point of seven and 14 days,
cells were washed three times with PBS and solubilized
in 0.1 % Triton X-100 (buffered in 0.1 mol/L PBS,
pH 7.3) at 4 °C for 1 h. After sonication and centrifuga-
tion, ALP activity in the supernatant was determined col-
orimetrically using readings OD405/OD562. Total protein
was quantified by BCA Protein Assay Kit (Thermo Fisher
Scientific Inc.). The ALP activity was normalized to the
total protein. Samples were run in triplicate with three
independent experiments performed.
Real-time PCR
MC3T3-E1 cells were seeded at a density of 2×105 and
cultured for 14 days as previously described [26, 28, 29].
The effects of rhBMP2_108 at various concentrations
were investigated on four osteogenic-related gene ex-
pression including alkaline phosphatase (ALP), collagen
I (COL I), runt-related transcription factor two (Runx 2)
and osteocalcin (OCN). Total RNA was extracted from
MC3T3-E1 cells by Trizol reagent (TriPure Isolation
Reagent, Roche Applied Science, Germany) according to
the manufacturer’s instructions. The concentration
and quality of the total RNA samples was analyzed by
Nanodrop (Thermo Fisher Scientific Inc.). Com-
plementary DNA was synthesized from 2 μg of total
RNA using RevertAidTm First Strand cDNA Synthesis Kit
(Fermentas) following the manufacturer’s protocol. RT-
qPCR was performed in 20 μL reactions containing 10 μl
SYBR Green Master Mix (Roche Applied Science,
Germany), 0.6 μL (10 μM) of each forward and reverse
primer for each gene of interest, 2 μL of cDNA template
and 6.8 μL water. The primer sequences (shown in Table 1)
have designed specifically according to the reference.
Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), a
reference gene, was used as a control. The reaction was
analyzed using an ABI Prism 7000 Sequence Detection
System (Applied Biosystems), and the PCR amplification
run for 40 cycles. To validate specific amplicon amplifica-
tion without genomic DNA contamination, melting curve
analysis was performed and the single apex appeared
around the annealing temperature. Relative expression
levels for each desired gene were normalized against the
Ct value of GAPDH and determined by using the delta Ct
method. All samples were determined in triplicate for
three independent studies.
Alizarin red quantification
Alizarin red staining was performed to determine the
presence of extracellular matrix mineralization after
14 days. MC3T3-E1 cells were seeded at a density of
50,000 cells per 24 well culture dish containing the various
concentrations of rhBMP2_108. After 14 days, cells were
fixed in 96 % ethanol for 15 min and stained with 2 % ali-
zarin red solution in water (pH 4.2) at room temperature
for 1 h and visualized under light microscopy. Thereafter,
alizarin red quantification was dissolved using 200 μl of
1 % cetylpyridinium chloride (dissolved with double
distilled water) at room temperature for 4 h. Then 100 μl
solution was transferred to 96-well plate to text OD 560.
Table 1 Primer sequences for osteoblast differentiation markers
GAPDH F GTGAAGGTCGGTGTGAACGG
GAPDH R TCCTGGAAGATGGTGATGGG
OPN F GAGGAAACCAGCCAAGGTAAG
OPN R AAAGCAAATCACTGCCAATCTC
OCN F GAGGACCATCTTTCTGCTCACT
OCN R CGGAGTCTGTTCACTACCTTATTG
ALP F TGTGGAATACGAACTGGATGAG
ALP R ATAGTGGGAATGCTTGTGTCTG
RUNX2 F GTGTTCCCTACTCAGCCGTC
RUNX2 R GAGGCCTCGGTCCACATTAG
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Statistical analysis
All data analysis was performed using GraphPad
Prism6.0 software. Normal distribution of sample data
was assumed for the current study and therefore para-
metric testing was analyzed using one-way ANOVA and
statistically significant values were adopted as p < 0.05.
Mean and standard error (SE) were analyzed using one-
way ANOVA with a post hoc test with Tukey’s analysis.
Results
Effect of rhBMP2_108 on cell recruitment
In order to investigate the effects of rhBMP2_108 on cell
recruitment, a transwell chamber was utilised at five
different concentrations of rhBMP2_108 (Fig. 1). It was
found that after a 24 h period, all concentrations of
rhBMP2_108 and control rhBMP2 were able to signifi-
cantly increase cell recruitment of MC3T3-E1 cells when
compared to control samples. Little variability between
samples was observed demonstrating a strong potential
for all concentrations of rhBMP2_108 to induce cell
recruitment (Fig. 1).
Effect of rhBMP2 on cell proliferation
The effect of rhBMP2_108 was investigated at five
concentrations and control rhBMP2 for their ability to
stimulate cell proliferation in vitro (Fig. 2). It was found
that MC3T3-E1 cells demonstrated very similar cell
number 1 day post-seeding irrespective of cell culture
media concentration of rhBMP2_108 (Fig. 2). A slight
increase in cell number was observed at 3 days, however,
no significant difference could be observed between the
various treatment modalities (Fig. 2). By 5 days post
seeding, a significant increase in cell number was ob-
served for MC3T3-E1 cells with all concentrations of
rhBMP2_108 used in this study (Fig. 2). Interestingly, no
advantages could be found for higher concentrations of
rhBMP2_108 when compared to their lower counter-
parts (Fig. 2).
Effect of rhBMP2 on cell differentiation
RhBMP2_108 was then assessed for its ability to speed up
osteoblast differentiation at various concentrations (Fig. 3,
Fig. 4, Fig. 5, Fig. 6). First it was found that rhBMP2_108
was able to significantly increase ALP activity at seven and
14 days post seeding for all concentrations of rhBMP2_108
(Fig. 3). Interestingly, it was observed at 7 days that ALP
activity was significantly higher at rhBMP2_108 concentra-
tions of 50, 100 and 200 ng/ml when compared to control
samples (Fig. 3). At 14 days, all treatment modalities
receiving rhBMP2_108 at various concentrations demon-
strated a marked 16-fold increase in ALP activity when
compared to control samples void of rhBMP2_108 (Fig. 3).
Then MC3T3-E1 cells were assessed for mRNA levels
by real-time PCR for genes encoding ALP, OCN, COL-1
and Runx2 at various concentrations of rhBMP2_108
(Fig. 4). For gene encoding Runx2, up to a five fold in-
crease was observed at a concentration of 500 ng/ml
when compared to control samples with a significant
increase at 100 and 200 ng/ml compared to lower con-
centrations (Fig. 4a). Similarly, COL-1 also demonstrated
concentration dependent increase in gene expression
(Fig. 4b). Here however, only up to a two fold increase
was observed relative to control samples (Fig. 4b). It was
observed that mRNA levels of ALP were over five fold in-
creased at 14 days at concentrations of ten and 50 ng/ml
rhBMP2_108 whereas at a concentration of 100 and
200 ng/ml 20 fold increase in ALP activity (Fig. 4c). The
highest concentration of 500 ng/ml demonstrated a 40
fold increase in ALP activity when compared to culture
media without rhBMP2 (Fig. 4c). The greatest fold change
Fig. 1 Cell recruitment assay demonstrated that all concentrations of rhBMP2_108 were significantly able to improve MC3T3-E1 cell recruitment
when compared to control samples with no rhBMP2 (Scale bar = 100 μm). All experiments were conducted in triplicate with three independent
experiments (n = 9). Data represents means +/− SEM. ** denotes all samples significantly higher than control samples, p < 0.01)
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was observed in OCN levels where up to a 300 fold in-
crease was observed when compared to their respective
control without rhBMP2 (Fig. 4d).
Lastly, alizarin red staining was used to visualize in vitro
mineralization (Fig. 5). It was observed that without
rhBMP2, MC3T3-E1 pre-osteoblasts were unable to gen-
erate any visual mineralization as observed by alizarin red
staining (Fig. 5). The effects of rhBMP2_108 demonstrated
a significant concentration dependent increase in alizarin
red staining at 14 days post seeding (Fig. 6).
Fig. 2 Cell number as calculated by an CCK-8 assay for MC3T3-E1 cells seeded at various concentrations of rhBMP2_108 when compared to control
tissue culture plastic (All experiments were conducted in triplicate with three independent experiments (n = 9). Data represents means +/− SEM.
# denotes control samples significantly lower than all other treatment modalities, p < 0.05)
Fig. 3 ALP activity was significantly increased at seven and 14 days post seeding for samples seeded with rhBMP2_108 when compared to control
tissue culture plastic alone (All experiments were conducted in triplicate with three independent experiments (n = 9). Data represents means +/− SEM.
* denotes significant difference between 500 ng/ml and 10 ng/ml rhBMP2, p < 0.05; ** denotes significantly higher than all other modalities, p < 0.05,
# denotes control samples significantly lower than all other treatment modalities, p < 0.05)
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Discussion
The aim of the present study was to investigate the bio-
activity of a shorter recombinant BMP2 (rhBMP2_108)
sequence on osteoblast behavior. The use of rhBMP2 for
orthopaedic and dental treatments has been utilised for
a number of procedures including open fractures, hip
reconstructive surgeries as well as guided bone regener-
ation procedures in dentistry [30–33]. Despite demon-
strating promising in vivo results, growth factor use has
had a mix of success when utilised for clinical use. Some
of the key concerns raised with respect to growth factor
utilisation is their transient bioactivity which has been sug-
gested could to be in the order of minutes to hours [18].
There are three main areas of research aimed at im-
proving the bioactivity of growth factors; 1) utilising gene
therapy, 2) improving protein stability or 3) improving the
growth factor delivery system. One method that has
shown early promise for growth factor delivery is that of
gene therapy where the use of viral vectors such as adeno-
virus may circumvent many of the limitations of protein
delivery by exhibiting a high in vivo transduction effi-
ciency with a relatively short expression period [34–38].
Their main advantage is the over-expressed protein is
constructed within the organisms main cell and thus has
access to a multitude of folding proteins capable of
accurately packaging and delivering growth factors to their
surrounding tissues [25, 39, 40]. Despite the advancements
made in this area of research, the use of gene therapy is
still prohibited by the FDA making its future clinical use
at the moment a future optimistic approach with no
known timetable for its eventual use. Furthermore, recent
strategies utilizing short synthetic BMP2-mimicking
Fig. 4 mRNA levels of (a) ALP, (b) OCN, (c) COL-1 and (d) Runx2 for MC3T3-E1 cells seeded at various concentrations of rhBMP2_108 (All experiments
were conducted in triplicate with three independent experiments (n = 9). Data represents means +/− SEM. * denotes p < 0.05; ** denotes significantly
higher than all other modalities, p < 0.05, # denotes control samples significantly lower than all other treatment modalities, p < 0.05)
Fig. 5 Qualitative analysis of alizarin red staining demonstrated increased mineralization for MC3T3-E1 cells at increasing concentrations of
rhBMP2_108 at 14 days post seeding
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peptides have been shown to facilitate bone regeneration
[41–44], however a lack of clinical reports utilizing such
strategies is still lacking.
Thus it becomes vital to find alternative methods that
may be deemed suitable for improvements in growth
factor bioactivity. In the present study, a novel recom-
binant version of BMP2 (rhBMP2_108) with a shorter
amino acid sequence. Prior to animal testing however, in
vitro testing was performed on cell activity. It was found
in the present study that r rhBMP2_108 was firstly able
to target the recruitment of progenitor cells by favouring
early and rapid recruitment of cells within 24 h (Fig. 1).
The homing of progenitor cells and stem cells is one of
the key initial stages in the early onset of fracture re-
pair and is a necessary component of wound healing
of bony-defects. As such, the ability for rhBMP2_108
to speed up the rate and number of progenitor cells to de-
fects sites is crucial for bone repair.
Although the effects as seen in the present study
demonstrated that rhBMP2_108 was significantly able to
induce cell proliferation, it was not observed in a concen-
tration dependent manner. This can be due to the fact
that cells undergoing cell differentiation are not prone to
proliferate simultaneously. While not much concentration
dependant observations were found for cell recruitment
or proliferation, significant differences were found for
osteoblast differentiation in response to rhBMP2_108. It
was observed that over a four fold increase in ALP activity
were detected with rhBMP2_108 and further concentra-
tion dependant increases in alizarin red staining further
validated our hypothesis that rhBMP2_108 acts primarily
by stimulating osteoblast differentiation. It was also
observed that a significant increase in mRNA levels of
ALP was observed in a concentration dependant manner.
Interestingly OCN, a late differentiation marker for osteo-
blasts was upregulated approximately 300 fold when com-
pared to control samples (Fig. 4b). This finding likely
signifies that the MC3T3-E1 pre-osteoblasts seeded in
control wells without rhBMP2 likely remained progenitor
cells and did not differentiate towards the osteoblast
lineage throughout the course of these experiments. This
is further evident by the fact that the samples without
rhBMP2 showed no mineralization potential in the
alizarin red experiments (Fig. 5).
Although the results from the present study confirm
the effects of this shorter amino acid sequence of
rhBMP2_108 on cell activity, much research remains
necessary in order to validate these findings in an animal
model prior to clinical testing. It remains virtually un-
known if the protein activity will be affected in vivo by
the shortened amino acid sequence and much future re-
search investigating this relationship both with respect
to protein half-life duration as well as its subsequent ef-
fects on bone formation need to be carefully evaluated.
Furthermore, its comparison to leading rhBMP2 cur-
rently available on the market with FDA approval is also
necessary to provide a better understanding on the
effects of protein amino acid length on bioactivity of
recombinant proteins.
Conclusion
The results from the present study demonstrate that a
shorter amino acid sequence of recombinant BMP2
(rhBMP2_108) retains bioactive properties of BMP2 when
compared to commercially available rhBMP2 in vitro. It
was shown that rhBMP2_108 was able to stimulate rapid
cell recruitment of MC3T3-E1 pre-osteoblasts and sup-
port their differentiation towards the osteoblast lineage in
Fig. 6 Quantitative analysis of alizarin red staining. rhBMP2_108 demonstrate a concentration dependent increase in alizarin red staining (All experiments
were conducted in triplicate with three independent experiments (n = 9). Data represents means +/− SEM. * denotes significant difference between
two groups, p < 0.05; ** denotes significantly higher than all other modalities, p < 0.05, # denotes control samples significantly lower than all other
treatment modalities, p < 0.05)
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a concentration dependant manner. Future in vivo
research analyzing the use of this amino acid sequence of
rhBMP2_108 is now necessary in critically-sized bone
defects. Furthermore, investigation on the optimal delivery
system this growth factor are necessary to potentially
further improve its bioactivity for clinical use.
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